Haleon plc (LON:HLN) Receives GBX 393.67 Consensus Target Price from Brokerages

Haleon plc (LON:HLN) has been given a consensus recommendation of “Hold” by the six brokerages that are covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is GBX 393.67.

A number of equities analysts have weighed in on HLN shares. Jefferies Financial Group dropped their target price on shares of Haleon from GBX 450 to GBX 400 and set a “buy” rating for the company in a research note on Tuesday, May 5th. JPMorgan Chase & Co. decreased their price target on shares of Haleon from GBX 335 to GBX 315 and set an “underweight” rating on the stock in a research note on Thursday, June 25th. Royal Bank Of Canada reissued a “sector perform” rating and issued a GBX 370 price target on shares of Haleon in a report on Thursday, April 30th. Deutsche Bank Aktiengesellschaft restated a “sell” rating and issued a GBX 325 price objective on shares of Haleon in a research report on Wednesday, July 1st. Finally, Berenberg Bank reaffirmed a “buy” rating and set a GBX 512 price objective on shares of Haleon in a report on Thursday, April 30th.

Haleon Stock Up 0.9%

Shares of LON HLN opened at GBX 373.30 on Thursday. Haleon has a 12-month low of GBX 317.80 and a 12-month high of GBX 416.10. The firm’s 50-day simple moving average is GBX 343.10 and its 200 day simple moving average is GBX 363.36. The company has a quick ratio of 0.93, a current ratio of 0.92 and a debt-to-equity ratio of 52.26. The company has a market cap of £32.88 billion, a price-to-earnings ratio of 20.18, a price-to-earnings-growth ratio of 1.49 and a beta of 0.24.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.